The spectrum of clinical trials aiming at personalizing medicine

Chinese Clinical Oncology

Volumn 3, Issue 2, 2014, Pages

  Le Tourneau, Christophe ^a,b   Kamal, Maud ^a   Alt, Marie ^a   Verlingue, Loic ^a   Servois, Vincent ^a   Sablin, Marie Paule ^a   Servant, Nicolas ^a,b   Paoletti, Xavier ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

Author keywords

Algorithms; Biomarkers; Clinical trials; High throughput technologies; Personalized medicine

Indexed keywords

EID: 84920937786     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2014.05.02     Document Type: Review

References (57)

1. Sleijfer S, Ballman K, Verweij J. The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. J Clin Oncol 2013;31:2246-8.
2. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
5. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9.
6. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
8. Ciriello G, Miller ML, Aksoy BA, et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013;45:1127-33.
9. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
10. Walker I, MacDonald F, Stuart H, et al. Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's Stratified Medicine Programme. J Clin Oncol 2013;31 (suppl; abstr 11094).
11. Rollins BJ, MacConaill LE, Wagle N, et al. PROFILE: Broadly based genomic testing for all patients at a major cancer center. J Clin Oncol 2013;31 (suppl; abstr 1531).
12. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24.
13. Rodón J, Saura C, Dienstmann R, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012;9:359-66.
14. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=745680&version=HealthProfessional&protocolsearchid=12174081
15. Available online: www.vicc.org
16. Bedard PL, Oza AM, Tsao MS, et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J Clin Oncol 2013;31 (suppl; abstr 11002).
17. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=745671&version=HealthProfessional&protocolsearchid=12176142
18. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. Clin Cancer Res 2012;18:6373-83.
19. Kaiser J. Rare cancer successes spawn 'exceptional' research efforts. Science 2013;340:263.
20. Available online: http://www.eacr.org/mpathcourse2012/presentations/E%20Voest_presentation.pdf
21. Hollebecque A, Massard C, De Baere T, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial-Interim results. J Clin Oncol 2013;31 (suppl; abstr 2512).
22. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014;15:267-74.
23. Vignot S, Besse B, André F, et al. Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 2012;84:301-13.
24. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012;30:2956-2962.
25. Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013;31:2167-72.
26. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-92.
27. Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011;17:667-77.
28. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-6.
29. Dienstmann R, Serpico D, Rodon J, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-71.
30. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
31. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=690229&version=HealthProfessional&protocolsearchid=12174127
32. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=691870&version=HealthProfessional&protocolsearchid=12174129
33. Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013;31:4562-8.
34. Barker AD, Sigman CC, Kelloff GJ, et al. -SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
35. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=724784&version=HealthProfessional&protocolsearchid=12174135
36. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=724783&version=HealthProfessional&protocolsearchid=12174139
37. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-9.
38. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28:4877-83.
39. Available online: http://www.cancer.gov/clinicaltrials/search/view?cdrid=749710&version=HealthProfessional&protocolsearchid=12176033
40. Le Tourneau C, Kamal M, Trédan O, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol 2012;7:253-65.
41. Kummar S. Molecular Profiling based Assignment of Cancer Therapy (MPACT). Proc NCI-EORT-ASCO meeting, 2013.
42. Available online: http://www.cancer-lyric.com/programme/programme-1/
43. Doroshow JH. Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 2010;28:4869-71.
44. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
45. Le Tourneau C, Servois V, Diéras V, et al. Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer 2012;106:854-7.
46. Le Tourneau C, Paoletti X, Servant N, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014. [Epub ahead of print].
47. O'Rawe J, Jiang T, Sun G, et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 2013;5:28.
48. Ratan A, Miller W, Guillory J, et al. Comparison of sequencing platforms for single nucleotide variant calls in a human sample. PLoS One 2013;8:e55089.
49. McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. Nature 2013;502:317-20.
50. Soria JC, Massard C, Izzedine H. From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol 2009;27:1359-61.
51. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
52. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
53. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
54. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
55. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
56. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
57. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.